MedTrace Logo

Effect of Dexmedetomidine and Total Intravenous Anesthesia on Endothelial Damage-Related Biomarkers

NCT06897696 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-01-06

No results posted yet for this study

Summary

This study aimed to evaluate whether dexmedetomidine has a protective effect on endothelial damage by measuring plasma syndecan1 and heparan sulphate levels in rhinoplasty patients who take propofol+remifentanyl infusion.

Conditions

  • Endothelial Damage
  • Dexmedetomidine
  • Syndecan 1
  • Heparan Sulpahate

Interventions

DRUG

Dexmedetomidine+propofol+remifentanyl group

The dexmedetomidine+TIVA group will receive a bolus of 0.8-1 µg/kg dexmedetomidine for 10 minutes followed by continuous dexmedetomidine infusion at a rate of 0.3-0.5 µg/kg/hour.

DRUG

propofol+remifentanyl group

propofol 5-8 mg/kg/h and remifentanil 5-10 µg/kg/h will be administered to all patients

Sponsors & Collaborators

  • Firat University

    lead OTHER

Principal Investigators

  • Gulsum Altuntas · Firat University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-10
Primary Completion
2025-10-31
Completion
2025-10-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06897696 on ClinicalTrials.gov